Last €127.45 EUR
Change Today 0.00 / 0.00%
Volume 5.7K
DIM On Other Exchanges
Symbol
Exchange
EN Paris
OTC US
Frankfurt
As of 11:38 AM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

sartorius stedim biotech (DIM) Snapshot

Open
€127.45
Previous Close
€127.45
Day High
€127.95
Day Low
€126.00
52 Week High
03/24/14 - €153.50
52 Week Low
07/15/13 - €96.75
Market Cap
2.2B
Average Volume 10 Days
4.7K
EPS TTM
€4.43
Shares Outstanding
17.0M
EX-Date
04/10/14
P/E TM
28.8x
Dividend
€1.20
Dividend Yield
0.94%
Current Stock Chart for SARTORIUS STEDIM BIOTECH (DIM)

Related News

No related news articles were found.

sartorius stedim biotech (DIM) Related Businessweek News

No Related Businessweek News Found

sartorius stedim biotech (DIM) Details

Sartorius Stedim Biotech S.A. provides various equipment and services for the development, quality assurance, and production processes of the biopharmaceutical industry worldwide. The company’s integrated solutions covering fermentation, filtration, purification, fluid management, process control, and lab technologies support the biopharmaceutical industry to develop and produce drugs. Its products include filter membranes, and single-use and reusable bioreactors, single-use bags, tubing, connectors, and containers, as well as filtration systems, filter integrity testing equipment, and sophisticated services. The company also offers laboratory instruments, including weighing, quality control, lab water purification, liquid handling, cell cultivation, filtration, and purification products, as well as spare parts and consumables. It serves biopharmaceutical, pharmaceutical, food, and chemical manufacturers, as well as research and development laboratories. The company was founded in 1870 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.

3,600 Employees
Last Reported Date: 04/28/14
Founded in 1870

sartorius stedim biotech (DIM) Top Compensated Officers

Chairman, Chairman of the Administrative Boar...
Total Annual Compensation: €875.0K
Executive Vice President of Operations & IT, ...
Total Annual Compensation: €551.0K
Executive Vice President of Research & Develo...
Total Annual Compensation: €549.0K
Execurtive Vice President of Marketing, Sales...
Total Annual Compensation: €540.0K
Compensation as of Fiscal Year 2012.

sartorius stedim biotech (DIM) Key Developments

Sartorius Stedim Biotech S.A. Presents at Gilbert Dupont Healthcare Conference, May-13-2014

Sartorius Stedim Biotech S.A. Presents at Gilbert Dupont Healthcare Conference, May-13-2014 . Venue: Paris, France.

Sartorius Stedim Biotech S.A. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2014; Provides Earnings Guidance for the Year 2014

Sartorius Stedim Biotech S.A. reported unaudited earnings results for the first quarter ended March 31, 2014. For the quarter, the company's sales revenue was EUR 154.0 million compared to EUR 138.0 million a year ago. The company achieved double-digit growth in sales revenue. This growth was to a certain extent fueled by the company's recent acquisitions. Compared to the very strong year-earlier quarter, order intake expanded at a more moderate pace. All main regions added to sales growth, with North America posting the high gains. Earnings before interest & taxes was EUR 24.5 million compared to EUR 21.7 million a year ago. Profit before tax was EUR 22.0 million compared to EUR 20.0 million a year ago. Net profit was EUR 15.6 million compared to EUR 14.0 million a year ago. Net profit attributable to equity holders of the company was EUR 15.6 million or EUR 1.01 per diluted share compared to EUR 13.7 million or EUR 0.89 per diluted share a year ago. Net cash flow from operating activities was EUR 13.9 million compared to EUR 7.0 million a year ago. Capital expenditure was EUR 11.3 million compared to EUR 6.2 million a year ago. EBITDA was EUR 33.3 million compared to EUR 28.8 million a year ago. EBITA was EUR 27.9 million compared to EUR 24.0 million a year ago. Underlying earnings per share were at EUR 1.18 compared with EUR 1.01 in the first quarter of 2013. Net debt at the end of the first quarter stood at EUR 128.9 million. Underlying net profit was EUR 18.1 million compared to EUR 15.6 million a year ago. Based on the company's first-quarter results, management confirms its full-year forecast for 2014. Sales revenue is expected to increase by about 11% to 14% in constant currencies, including approx. 6% points of non-organic growth from recent acquisitions. The underlying EBITDA margin is projected to rise to approx. 23.5% in constant currencies. Furthermore, the Capex ratio is expected to be in the range of 6% to 8%.

Sartorius Stedim Biotech S.A., Q1 2014 Earnings Call, Apr 28, 2014

Sartorius Stedim Biotech S.A., Q1 2014 Earnings Call, Apr 28, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DIM:FP €127.45 EUR 0.00

DIM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Corning Inc $21.69 USD +0.06
General Electric Co $26.55 USD +0.35
Pall Corp $82.20 USD -0.07
Thermo Fisher Scientific Inc $118.27 USD +1.12
View Industry Companies
 

Industry Analysis

DIM

Industry Average

Valuation DIM Industry Range
Price/Earnings 28.4x
Price/Sales 3.2x
Price/Book 3.9x
Price/Cash Flow 31.5x
TEV/Sales 3.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SARTORIUS STEDIM BIOTECH, please visit www.sartorius.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.